{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:27:46Z","timestamp":1777530466906,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an important role in atherothrombosis independent of the cholesterol level. Acute-phase reactants, such as C-reactive protein, increase in patients with coronary artery disease and are known to predict adverse outcomes in such patients. The recent CANTOS trial published in The New England Journal of Medicine provides evidence that interleukin-1\u03b2 along with other cytokines play central roles in the inflammatory reaction that drives the interleukin-6 signaling pathway and have profound effects on cardiovascular outcomes. Several other ongoing studies are focused on multiple immune mediators involved in this process to support the inflammatory hypothesis of cardiovascular diseases. These new classes of drugs could represent the biggest breakthrough in cardiovascular medicine, which could have the greatest impact on cardiovascular mortality since the advent of statins. The drug canakinumab has shown promise in lowering atherosclerosis, and other drugs, such as colchicine and methotrexate, are gaining interest and are being investigated in multiple ongoing trials. A major concern is the affordability of these drugs, as most cardiovascular diseases are noted among people of lower socioeconomic statuses. The LoDoCo trial showed some benefits of colchicine, and whether this old drug can be marketed with a new label for cardiovascular disease remains in question. Therefore, a clear understanding of the different inflammatory pathways involved in atherosclerosis is needed to help develop more effective treatment modalities that will benefit humankind.<\/jats:p>","DOI":"10.1177\/1074248418778548","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T22:04:14Z","timestamp":1526940254000},"page":"483-493","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["The Utility of Anti-Inflammatory Agents in Cardiovascular Disease"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-6804","authenticated-orcid":false,"given":"Santhosh J.","family":"Kottoor","sequence":"first","affiliation":[{"name":"Department of Cardiology, Samaritan Heart Institute, Pazhanganad, Ernakulam, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit R.","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Chicago Medical School, Rosalind Franklin University, North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"bibr1-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"bibr2-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu203"},{"key":"bibr3-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1709904"},{"key":"bibr4-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1038\/nature10146"},{"key":"bibr5-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/83.2.456S"},{"key":"bibr6-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.06.006"},{"key":"bibr7-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1126\/science.1230719"},{"key":"bibr8-1074248418778548","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363"},{"key":"bibr9-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1002\/art.25009"},{"key":"bibr10-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139858.69915.2E"},{"key":"bibr11-1074248418778548","unstructured":"Zoccai G, Peruzzi M, Romagnoli E. Is the pathophysiology of plaque injury in acute mi changing? revisiting plaque erosion vs. rupture. Am Coll Cardiol. http:\/\/www.acc.org\/latest-in-cardiology\/articles\/2016\/02\/26\/09\/34\/is-the-pathophysiology-of-plaque-injury-in-acute-mi-changing. 2017. Accessed September 7, 2017."},{"key":"bibr12-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.868299"},{"key":"bibr13-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"bibr14-1074248418778548","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.6.3463"},{"issue":"2","key":"bibr15-1074248418778548","doi-asserted-by":"crossref","first-page":"ii68","DOI":"10.1136\/ard.62.suppl_2.ii68","volume":"62","author":"Choy E","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"bibr16-1074248418778548","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2015.0191"},{"key":"bibr17-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1002\/art.10623"},{"key":"bibr18-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"bibr19-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60110-X"},{"key":"bibr20-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"bibr21-1074248418778548","unstructured":"Wikipedia contributors. Interleukin-1 family. Wikipedia, The Free Encyclopedia. 2017. https:\/\/en.wikipedia.org\/w\/index.php?title=Interleukin-1_family&oldid=791078133. Updated May 10, 2018. Accessed October 20, 2017."},{"key":"bibr22-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.09.015"},{"key":"bibr23-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1038\/nature09663"},{"key":"bibr24-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938"},{"key":"bibr25-1074248418778548","unstructured":"Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived heart attack. https:\/\/www.novartis.com\/news\/media-releases\/novartis-phase-iii-study-shows-acz885-canakinumab-reduces-cardiovascular-risk. 2017. Updated June 22, 2017. Accessed September 7, 2017."},{"key":"bibr26-1074248418778548","first-page":"174","volume":"124","author":"Ridker PM","year":"2013","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"bibr27-1074248418778548","unstructured":"Cardiovascular Inflammation Reduction Trial (CIRT). US National Library of Medicine website. ClinicalTrials.gov identifier: NCT01594333. 2012. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01594333. Updated August 23, 2017. Accessed October 5, 2017."},{"key":"bibr28-1074248418778548","unstructured":"About CIRT\/Cardiovascular Inflammation Reduction Trial. theCIRT.org website. http:\/\/www.thecirt.org\/about-cirt.html. 2017. Accessed October 5, 2017."},{"key":"bibr29-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1186\/ar1914"},{"key":"bibr30-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem279"},{"key":"bibr31-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206074"},{"key":"bibr32-1074248418778548","doi-asserted-by":"publisher","DOI":"10.2174\/1871523011312010004"},{"key":"bibr33-1074248418778548","unstructured":"Colchicine Cardiovascular Outcomes Trial (COLCOT). US National Library of Medicine website. ClinicalTrials.gov identifier: NCT02551094. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02551094. Updated March 8, 2018. Accessed March 12, 2018."},{"key":"bibr34-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2015.01.004"},{"key":"bibr35-1074248418778548","unstructured":"Kumbhani DJ, Bhatt DL. Low dose colchicine for secondary prevention of cardiovascular disease. Am Coll Cardiol. 2012. http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2012\/12\/26\/11\/52\/lodoco#references-for-article."},{"key":"bibr36-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel332"},{"key":"bibr37-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3130-8"},{"key":"bibr38-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu224"},{"key":"bibr39-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.29035"},{"key":"bibr40-1074248418778548","unstructured":"Wikipedia contributors. Etanercept. Wikipedia, The Free Encyclopedia. 2017. https:\/\/en.wikipedia.org\/wiki\/Etanercept. Updated March 3, 2018. Accessed October 20, 2017."},{"key":"bibr41-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204345"},{"key":"bibr42-1074248418778548","unstructured":"A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors. US National Library of Medicine website. ClinicalTrials.gov identifier: NCT01331837. 2011. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01331837. Updated July 13, 2017. Accessed September 21, 2017."},{"issue":"6","key":"bibr43-1074248418778548","first-page":"1157","volume":"69","author":"Kim SC","year":"2017","journal-title":"Arthritis Rheum"},{"key":"bibr44-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282836"},{"key":"bibr45-1074248418778548","unstructured":"VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16). US National Library of Medicine website. ClinicalTrials.gov identifier: NCT01130246. 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01130246. Updated October 31, 2012. Accessed October 22, 2017."},{"key":"bibr46-1074248418778548","unstructured":"The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). US National Library of Medicine website. ClinicalTrials.gov identifier: NCT00799903. 2008. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00799903. Updated August 10, 2010. Accessed October 22, 2017."},{"key":"bibr47-1074248418778548","doi-asserted-by":"publisher","DOI":"10.5339\/gcsp.2015.6"},{"key":"bibr48-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.003"},{"key":"bibr49-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.071"},{"key":"bibr50-1074248418778548","unstructured":"A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. US National Library of Medicine website. ClinicalTrials.gov identifier: NCT01245634. 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01245634. Updated November 2, 2016. Accessed October 23, 2017."},{"key":"bibr51-1074248418778548","unstructured":"Gruberg L. ARISE: Effects of succinobucol, an antioxidant and anti-inflammatory, on clinical events in patients with acute coronary syndrome. Medscape website. https:\/\/www.medscape.com\/viewarticle\/554877, 2007. Accessed October 28, 2017."},{"key":"bibr52-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12114"},{"key":"bibr53-1074248418778548","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2013.0045"},{"issue":"1","key":"bibr54-1074248418778548","first-page":"e28997","volume":"5","author":"Hajsadeghi S","year":"2016","journal-title":"Res Cardiovasc Med"},{"key":"bibr55-1074248418778548","doi-asserted-by":"publisher","DOI":"10.4137\/CMC.S32804"},{"issue":"1","key":"bibr56-1074248418778548","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13063-016-1168-9","volume":"17","author":"Li Z","year":"2016","journal-title":"Trials"},{"key":"bibr57-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.8.793"},{"key":"bibr58-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01289-X"},{"key":"bibr59-1074248418778548","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.01.003"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418778548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248418778548","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418778548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:49Z","timestamp":1777394569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248418778548"}},"subtitle":["A Novel Perspective on the Treatment of Atherosclerosis"],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1177\/1074248418778548"],"URL":"https:\/\/doi.org\/10.1177\/1074248418778548","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]}}}